Neuroinflammatory events after anti-TNFα therapy

Ann Rheum Dis. 2022 May;81(5):e73. doi: 10.1136/annrheumdis-2020-217723. Epub 2020 May 20.

Authors

Evripidis Kaltsonoudis¹, Eleftherios Pelechas¹, Paraskevi V Voulgari¹, Alexandros A Drosos²

Affiliations

¹ Internal Medicine, Division of Rheumatology, University of Ioannina Faculty of Medicine, Ioannina, Greece.
² Internal Medicine, Division of Rheumatology, University of Ioannina Faculty of Medicine, Ioannina, Greece adrosos@cc.uoi.gr.

PMID: 32434825
DOI: 10.1136/annrheumdis-2020-217723

No abstract available

Keywords: adalimumab; etanercept; infliximab; magnetic resonance imaging; tumor necrosis factor inhibitors.

Publication types

Letter
Comment

MeSH terms

Adalimumab / therapeutic use
Etanercept / therapeutic use
Humans
Infliximab / therapeutic use
Receptors, Tumor Necrosis Factor*
Tumor Necrosis Factor-alpha*

Substances

Receptors, Tumor Necrosis Factor
Tumor Necrosis Factor-alpha
Infliximab
Adalimumab
Etanercept